Hypoxia potentiates allergen induction of HIF-1α, chemokines, airway inflammation, TGF-β1, and airway remodeling in a mouse model

Clinical Immunology

Volumn 147, Issue 1, 2013, Pages 27-37

  Baek, Kwang Je ^a,e   Cho, Jae Youn ^a   Rosenthal, Peter ^a   Alexander, Laura E Crotty ^a,b   Nizet, Victor ^c,d   Broide, David H ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e Konkuk University School of Medicine   (South Korea)

Author keywords

Eosinophil; ; Eotaxin 1; Hypoxia; ; KC; ; Neutrophil;

Indexed keywords

ALLERGEN; EOTAXIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 5; OVALBUMIN; TRANSFORMING GROWTH FACTOR BETA1;

AIRWAY REMODELING; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTHMA; BRONCHUS MUSCLE; CONTROLLED STUDY; DISEASE EXACERBATION; EOSINOPHIL COUNT; GENE TARGETING; HYPOXIA; IMMUNOHISTOCHEMISTRY; LUNG FIBROSIS; LUNG FUNCTION; MOUSE; MUCUS SECRETION; NEUTROPHIL COUNT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY TRACT INFLAMMATION;

AIRWAY REMODELING; ALLERGENS; ANIMALS; ANOXIA; ASTHMA; BRONCHI; CHEMOKINE CCL11; CHEMOKINES; CYTOKINES; DISEASE MODELS, ANIMAL; EOSINOPHILS; FIBROSIS; GENE EXPRESSION; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; LUNG; MICE; MICE, INBRED BALB C; NEUTROPHILS; OVALBUMIN; RESPIRATORY SYSTEM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84875275285     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2013.02.004     Document Type: Article

References (43)

1. McFadden E.R., Lyons H.A. Arterial-blood gas tension in asthma. N. Engl. J. Med. 1968, 278:1027-1032.
2. Eckert D.J., Catcheside P.G., Smith J.H., Frith P.A., McEvoy R.D. Hypoxia suppresses symptom perception in asthma. Am. J. Respir. Crit. Care Med. 2004, 169:1224-1230.
3. Fahy J.V., Kim K.W., Liu J., Boushey H.A. Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J. Allergy Clin. Immunol. 1995, 95:843-852.
4. Lamblin C., Gosset P., Tillie-Leblond I., Saulnier F., Marquette C.H., Wallaert B., Tonnel A.B. Bronchial neutrophilia in patients with noninfectious status asthmaticus. Am. J. Respir. Crit. Care Med. 1998, 157:394-402.
5. Ordonez C.L., Shaughnessy T.E., Matthay M.A., Fahy J.V. Increased neutrophil numbers and IL-8 levels in airway secretions in acute severe asthma: clinical and biologic significance. Am. J. Respir. Crit. Care Med. 2000, 161:1185-1190.
6. Wang F., He X.Y., Baines K.J., Gunawardhana L.P., Simpson J.L., Li F., Gibson P.G. Different inflammatory phenotypes in adults and children with acute asthma. Eur. Respir. J. 2011, 38:567-574.
7. Bai T.R., Vonk J.M., Postma D.S., Boezen H.M. Severe exacerbations predict excess lung function decline in asthma. Eur. Respir. J. 2007, 30:452-456.
8. O'Byrne P.M., Pedersen S., Lamm C.J., Tan W.C., Busse W.W., START Investigators Group Severe exacerbations and decline in lung function in asthma. Am. J. Respir. Crit. Care Med. 2009, 179:19-24.
9. Eltzschiz H.K., Carmeliet P. Hypoxia and inflammation. N. Engl. J. Med. 2011, 364:656-665.
10. Semenza G.L. Hypoxia inducible factors in physiology and medicine. Cell 2012, 148:399-408.
11. Greer S.N., Metcalf J.L., Wang Y., Ohh M. The updated biology of hypoxia-inducible factor. EMBO J. 2012, 31:2448-2460.
12. Broide D.H., Lotz M., Cuomo A.J., Coburn D.A., Federman E.C., Wasserman S.I. Cytokines in symptomatic asthma airways. J. Allergy Clin. Immunol. 1992, 89:958-967.
13. Norzlia M.Z., Fakes K., Henry R.L., Simpson J., Gibson P.G. Interleukin-8 secretion and neutrophil recruitment accompanies induced sputum eosinophil activation in children with acute asthma. Am. J. Respir. Crit. Care Med. 2000, 161:769-774.
14. Lee C.G., Link H., Baluk P., Homer R.J., Chapoval S., Bhandari V., Kang M.J., Cohn L., Kim Y.K., McDonald D.M., Elias J.A. Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nat. Med. 2004, 10:1095-1103.
15. Inscore S.C., Stenmark K.R., Orton C., Irvin C.G. Neonatal calves develop airflow limitation due to chronic hypobaric hypoxia. J. Appl. Physiol. 1991, 70:384-390.
16. Estrada K.D., Chesler N.C. Collagen-related gene and protein expression changes in the lung in response to chronic hypoxia. Biomech. Model. Mechanobiol. 2009, 8:263-272.
17. Cogo A., Napolitano G., Michoud M.C., Barbon D.R., Ward M., Martin J.G. Effects of hypoxia on rat airway smooth muscle cell proliferation. J. Appl. Physiol. 2003, 94:1403-1409.
18. L.E. Crotty Alexander, K. Akong, S. Feldstein, P. Johansson, A. Nguyen, E.K. McEachern, S. Nicatia, A.S. Cowburn, J. Olson, J.Y. Cho, H. Isaacs, R.S. Johnson, D.H. Broide, V. Nizet V, Myeloid Cell HIF-1α Regulates Asthma Airway Resistance and Eosinophil Function. J. Mol. Med. (in press).
19. Nizet V., Johnson R.S. Interdependence of hypoxic and innate immune responses. Nat. Rev. Immunol. 2009, 17:609-617.
20. Huerta-Yepez S., Baay-Guzman G.J., Garcia-Zepeda R., Hernandez-Pando R., Vega M.I., Gonzalez-Bonilla C., Bonavida B. 2-Methoxyestradiol (2-ME) reduces the airway inflammation and remodeling in an experimental mouse model. Clin. Immunol. 2008, 129:313-324.
21. Ahmad T., Kumar M., Mabalirajan U., Pattnaik B., Aggarwal S., Singh R., Singh S., Mukerji M., Ghosh B., Agrawal A. Hypoxia response in asthma: differential modulation on inflammation and epithelial injury. Am. J. Respir. Cell Mol. Biol. 2012, 47:1-10.
22. Huerta-Yepez S., Baay-Guzman G.J., Bebenek I.G., Hernandez-Pando R., Vega M.I., Chi L., Riedl M., Diaz-Sanchez D., Kleerup E., Tashkin D.P., Gonzalez F.J., Bonavida B., Zeidler M., Hankinson O. Hypoxia inducible factor promotes murine allergic airway inflammation and is increased in asthma and rhinitis. Allergy 2011, 66:909-918.
23. Ikeda R.K., Miller M., Nayar J., Walker L., Cho J.Y., McElwain K., McElwain S., Raz E., Broide D.H. Accumulation of peribronchial mast cells in a mouse model of ovalbumin allergen induced chronic airway inflammation: modulation by immunostimulatory DNA sequences. J. Immunol. 2003, 171:4860-4867.
24. Miller M., Tam A.B., Cho J.Y., Doherty T.A., Pham A., Khorram N., Rosenthal P., Mueller J.L., Hoffman H.M., Suzukawa M., Niwa M., Broide D.H. ORMDL3 is an inducible lung epithelial gene regulating metalloproteases, chemokines, OAS, and ATF6. Proc. Natl. Acad. Sci. 2012, 109:16648-16653.
25. Cho J.Y., Miller M., Baek K.J., Han J.W., Nayar J., Lee S.Y., McElwain K., McElwain S., Friedman S., Broide D.H. Inhibition of airway remodeling in IL-5-deficient mice. J. Clin. Invest. 2004, 113:551-560.
26. Kobayashi Y. Neutrophil infiltration and chemokines. Crit. Rev. Immunol. 2006, 26:307-316.
27. Rothenberg M.E., MacLean J.A., Pearlman E., Luster A.D., Leder P. Targeted disruption of the chemokine eotaxin partially reduces antigen-induced tissue eosinophilia. J. Exp. Med. 1997, 185:785-790.
28. Wills-Karp M., Luyimbazi J., Xu X., Schofield B., Neben T.Y., Karp C.L., Donaldson D.D. Interleukin-13: central mediator of allergic asthma. Science 1998, 282:2258-2261.
29. Broide D.H., Campbell K., Gifford T., Sriramarao P. Inhibition of eosinophilic inflammation in allergen-challenged, IL-1 receptor type 1-deficient mice is associated with reduced eosinophil rolling and adhesion on vascular endothelium. Blood 2000, 95:263-269.
30. Heaney L.G., Brightling C.E., Menzies-Gow A., Stevenson M., Niven R.M., British Thoracic Society Difficult Asthma Network Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry. Thorax 2010, 65:787-794.
31. Moore W.C., Bleecker E.R., Curran-Everett D., et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J. Allergy Clin. Immunol. 2007, 119:405-413.
32. Cox G. Glucocorticoid treatment inhibits apoptosis in human neutrophils. J. Immunol. 1995, 154:4719-4725.
33. Haldar P., Brightling C.E., Hargadon B., et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med. 2009, 360:973-984.
34. Green R.H., Brightling C.E., McKenna S., et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002, 30:1715-1721.
35. Pavord I.D., Korn S., Howarth P., Bleecker E.R., Buhl R., Keene O.N., Ortega H., Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012, 380:651-659.
36. Nair P., Pizzichini M.M., Kjarsgaard M., et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N. Engl. J. Med. 2009, 360:985-993.
37. Haldar P., Pavord I.D., Shaw D.E., et al. Cluster analysis and clinical asthma phenotypes. Am. J. Respir. Crit. Care Med. 2008, 178:218-224.
38. Lasserson T.J., Ferrara G., Casali L. Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. Cochrane Database Syst. Rev. 2011, 12:CD004106.
39. Nissim Ben Efraim A.H., Eliashar R., Levi-Schaffer F. Hypoxia modulates human eosinophil function. Clin. Mol. Allergy 2010, 8:10.
40. Le A.V., Cho J.Y., Miller M., McElwain S., Golgotiu K., Broide D.H. Inhibition of allergen-induced airway remodeling in Smad 3-deficient mice. J. Immunol. 2007, 178:7310-7316.
41. Flood-Page P., Menzies-Gow A., Phipps S., Ying S., Wangoo A., Ludwig M.S., Barnes N., Robinson D., Kay A.B. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J. Clin. Invest. 2003, 112:1029-1036.
42. Green R.M., Custovic A., Sanderson G., Hunter J., Johnston S.L., Woodcock A. Synergism between allergens and viruses and risk of hospital admission with asthma: case-control study. BMJ 2002, 324:1131-1135.
43. Yamaji-Kegan K., Su Q., Angelini D.J., Johns R.A. IL-4 is proangiogenic in the lung under hypoxic conditions. J. Immunol. 2009, 182:5469-5476.